CDSCO vs FDA Medical Device Approvals: Key Differences in Classification, Pathways, and Requirements

The Central Drugs Standard Control Organisation (CDSCO) in India and the U.S. Food and Drug Administration (FDA) both regulate medical devices using risk-based systems to ensure safety and effectiveness. While aligned on core principles, differences in stringency, timelines, clinical data requirements, and post-market oversight make dual-market strategies essential for manufacturers. As of 2026, CDSCO continues refinements under the Medical Devices Rules, 2017 (with perpetual licensing and software guidance), while FDA maintains robust pathways like Breakthrough Devices Program.

Both classify devices by risk: CDSCO into Classes A–D (low to high), FDA into Classes I–III. Higher classes face stricter controls in both.

Major Comparison Areas

Aspect	CDSCO (India)	FDA (United States)
Regulatory Framework	Medical Devices Rules, 2017 (amended 2025–2026); perpetual validity with retention fees	Federal Food, Drug, and Cosmetic Act; 21 CFR Parts 800–1299
Classification	Class A (low), B (low-moderate), C (moderate-high), D (high); non-sterile/non-measuring Class A often exempt	Class I (low), II (moderate), III (high); based on predicate devices
Premarket Pathways	Registration/licensing via SUGAM portal; import/manufacturing licenses (MD forms); often relies on Free Sale Certificate from GHTF countries	510(k) for substantial equivalence; PMA for high-risk; De Novo for novel low/moderate-risk; exemptions for many Class I
Clinical Data Requirements	Varies by class; often accepts overseas data for lower risk; local trials sometimes needed for higher/novel	Extensive for Class III (PMA); bench/testing often suffices for 510(k); rigorous trials for novel
Timelines	6–9 months typical (faster for lower risk)	90–180 days for 510(k); 1+ year for PMA; accelerated options like Breakthrough
QMS Requirements	ISO 13485 mandatory	QMSR (aligning with ISO 13485 as of Feb 2026); previously QSR
Post-Market Surveillance	Developing (Materiovigilance Programme); less mature than FDA	Robust (MDR reporting, recalls, inspections)
Inspections/Audits	Risk-based; increasing but less frequent/rigorous	Frequent unannounced inspections; high enforcement
Fees	Lower (e.g., ~$1,000/site + per device for import)	Higher user fees (e.g., $11,000+ annual establishment)

Approval Pathways Breakdown

• Low-Risk Devices → CDSCO: Often registration only (Class A exempt from full licensing). FDA: Many Class I exempt from premarket; general controls.
• Moderate-Risk → CDSCO: License via MD forms; substantial equivalence or overseas approvals accepted. FDA: 510(k) clearance showing equivalence to predicate (most common pathway).
• High-Risk/Novel → CDSCO: Detailed review; may require local data for Class D. FDA: PMA with clinical trials; De Novo for down-classification of novel devices without predicate.
• Accelerated Options → CDSCO: Limited; relies on global approvals. FDA: Breakthrough Devices Program (faster review for innovative tech).

Implications for Manufacturers

FDA approvals are more stringent and time-intensive upfront but offer global gold-standard credibility. CDSCO is comparatively faster and cost-effective for the Indian market but evolving toward greater harmonization (e.g., reliance on ISO 13485, software guidance). Many manufacturers pursue FDA first, then leverage approvals (via Free Sale Certificate) for CDSCO to streamline entry into India.

For U.S. or Indian market access, consult official portals (cdsco.gov.in or fda.gov) for latest checklists, as regulations update frequently (e.g., CDSCO’s 2026 oncology classifications).

By Mark Smith

Follow us on X @realnewshubs and subscribe for push notifications.

Follow and subscribe us increase push notification.

FAQ Schema

Question: What is the main difference between CDSCO and FDA device classification? Answer: Both are risk-based (A–D in CDSCO vs I–III in FDA), but FDA relies heavily on predicate devices for clearance, while CDSCO often accepts overseas approvals.

Question: Is CDSCO approval faster than FDA? Answer: Yes—typically 6–9 months vs FDA’s 3–12+ months depending on pathway (510(k) faster, PMA longer).

Question: Does CDSCO require clinical trials like FDA? Answer: Less frequently; often waived with global data, unlike FDA’s rigorous requirements for Class III/novel devices.

Question: Can FDA approval help with CDSCO registration? Answer: Yes—Free Sale Certificate from FDA is commonly used to support CDSCO import/manufacturing licenses.

Review Schema

Item Reviewed: CDSCO vs FDA Medical Device Approval Processes Reviewer: Mark Smith Review Rating: 4.7/5 Review Body: Comprehensive risk-based systems with FDA offering more rigor and innovation pathways (e.g., De Novo), while CDSCO provides faster access to India’s market—key for global strategies in 2026 amid harmonization efforts.